. 2019 Oct 15;39(6):1185–1197. doi: 10.1038/s41388-019-1053-6

Table 1.

Characteristics of CLL patients

Patient no.	Age at diagnosis	Gender	Binet/Rai stage	Previous treatment	%CD19/ CD5^a	IGVH status	NOTCH1 status^b	NOTCH1 mutation^b	%NOTCH1-mutation	Cytogenetic alterations^c
CLL 1	77	F	B/II	Fludarabine, FC	82	UNMUT	MUT	p2515fs*4	50	11q del, 13q del
CLL 2	45	M	A/II	No	85	UNMUT	MUT	p2515fs*4	43	13q del
CLL 3	62	F	C/III	2CdA, chlorambucil, CHOP-like, FCM	93	ND	MUT	p2515fs*4	>40^d	13q del
CLL 4	54	M	B/II	No	90	UNMUT	MUT	p2515fs*4	70	Normal
CLL 5	60	F	A/0	No	87	MUT	MUT	p2515fs*4	>40^d	13q del
CLL 6	54	M	A/0	No	90	UNMUT	MUT	p2515fs*4	9	Normal
CLL 7	69	M	A/0	No	90	UNMUT	MUT	p2515fs*4	48	trisomy 12
CLL 8	77	F	B/II	No	92	UNMUT	MUT	p2515fs*4	50	11q del, 13q del
CLL 9	77	M	A/I	Chlorambucil	86	UNMUT	MUT	p2515fs*4	53	11q del, trisomy 12
CLL 10	61	F	BII	No	81	ND	MUT	p2515fs*4	>40^d	13q del
CLL 11	64	M	C/IV	Chlorambucil, fludarabine	65	UNMUT	MUT	p2515fs*4	>40^d	Normal
CLL 12	59	F	B/II	Fludarabine, R-FCM	94	UNMUT	MUT	p2515fs*4	15	11q del, 13q del
CLL 13	44	M	B/II	No	97	UNMUT	UNMUT	UNMUT	–	13q del
CLL 14	61	M	C/III	No	96	UNMUT	UNMUT	UNMUT	–	11q del
CLL 15	75	M	B/II	No	91	UNMUT	UNMUT	UNMUT	–	11q del
CLL 16	71	M	C/IV	Ibrutinib, chlorambucil, bendamustine	96	UNMUT	UNMUT	UNMUT	–	Normal
CLL 17	59	M	B/II	No	95	UNMUT	UNMUT	UNMUT	–	Normal
CLL 18	71	M	A/0	No	97	UNMUT	UNMUT	UNMUT	–	Normal
CLL 19	58	M	B/II	FCM	95	UNMUT	UNMUT	UNMUT	–	13q del
CLL 20	55	M	BII	CHOP	86	UNMUT	UNMUT	UNMUT	–	13q del
CLL 21	63	F	BII	Fludarabine, FCM, CHOP	90	UNMUT	UNMUT	UNMUT	–	Normal

M male, F female, UNMUT unmutated, MUT mutated, ND not determined, del deletion, FCM fludarabine, cyclophosphamide, mitoxantrone, CHOP cyclophosphamide, doxorubicin, vincristine, prednisone, 2CdA cladribine, R rituximab

^aQuantified by flow cytometry

^bAll the mutations have a frequency of >20%

^cAssessed by FISH

^dSanger sequencing data